srpt closed at 14; ran to 45 the next day on deushane muscular dystrophy results which effects small number of patients
steller results and this gaps 20 + or a lot more
Sentiment: Strong Buy
There's no doubt that extensive validation would be required, and that 90% is far less than optimal. But when you have nothing, something looks pretty good. It's a start. We could say the same thing about PBT2. It may not turn out to be a miracle cure, but on the other hand, it may turn out to be the starting point for effective treatment. That would still be an exciting development.
Expecting $8 if PBT2 shows no benefit vs placebo, you might want take your own advice about considering the possibility you may be wrong.
agree, what we will have are panic sellers just wanting to get out at any price or chasers trying to time with limits but it will only keep getting away from them
This seems interesting, but a long way from a dependable diagnostic that some might believe by superficial examination of press releases. Also, this serves as a reminder that the FDA and medical community requires strong statistical verification, especially when looking at small trials.
From MedpageToday and Nature, News and Comments.
the 10-marker panel had an area under the receiver-operating characteristic curve (AU-ROC) of 0.92 (95% CI 0.87-0.99), with sensitivity and specificity each at 90%...If the study cohort's 5% rate of conversion from normal cognition to mild impairment or Alzheimer's disease is representative of a real-world screening population, then the test would have a positive predictive value of just 35%. That is, nearly two-thirds of positive screening results would be false.
In general, a positive predictive value of 90% is considered the minimum for any kind of screening test in normal-risk individuals....Statistical modeling suggested an optimal set of cutoffs for the 10 markers to distinguish impaired individuals from controls...The model actually did less well in discriminating the entire group of impaired participants from normal controls (AU-ROC 0.77) than in predicting who would convert from normal to impaired (AU-ROC 0.92).
“These findings are potentially very exciting,” says Simon Lovestone, a neuroscientist at the University of Oxford, UK, and a coordinator of a major European public-private partnership seeking biomarkers for similar to those of Alzheimer's disease during the latest work. “So the findings need to be confirmed in independent and larger studies.”
In a more restrained vein than Federoff took in the press release, the Nature Medicine report concluded by saying their biomarker panel "requires external validation using similar rigorous clinical classification before further development for clinical use. Such additional validation should be considered in a more diverse demographic group than our initial cohort."
I know what opening range means. Forget digesting the news. The stock is going to gap way down if the drug has no efficacy and way up if it is a home run.
You will not be able to get out at 7 or in at 15 as circumstances apply.
With all of the preliminary info indicating positive why would anyone sell? If you're in this stock for it's potential why sell because it isn't going up prior to them announcing the results of the trial. Yes there are shorts all over this but that is all the more reason to hold if you're long.
Sentiment: Strong Buy
Do you rookies even know what OPENING range means? That is the time when few have had time to digest the news. I do not disparage you ONE WAY BULLS. Notice I didn't try to suggest a CLOSE. Here's a bit of advice...when you make an investment (or speculation) ALWAYS CONSIDER the possibility that you may be wrong and be prepared to withstand the results. I have a sizable long position in this stock and am a Big Boy about what might happen.
A bear raid is not just a quick sell off by any means possible.
Here is the NASDAQ definition:
A "bear raid" is when short-sellers conspire to push down the price of a stock through coordinated short-selling or the spreading of false rumors (or both)."
We have not seen either the huge spike in short selling and/or the type of false rumors that would constitute a bear raid.
1. I would knock an extra $5 off that range because the stock is potentially worthless at that point.
2. I agree
4. way higher.
Since PBT-2 works best the earlier detected this should make things all come together to benefit the patient at the earliest stage of diagnoses and begin treatment with PBT-2 immediately.
Don't ya love when a plan comes together?